Welcome to our dedicated page for Iterum Therapeutics Plc SEC filings (Ticker: ITRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iterum Therapeutics plc (ITRM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Iterum’s financial condition, commercialization of ORLYNVAH™, capital-raising activities and Nasdaq listing status.
Investors can review Iterum’s current reports on Form 8-K, which have covered topics such as quarterly financial results, the U.S. commercial launch of ORLYNVAH™ (oral sulopenem) for certain uncomplicated urinary tract infections in adult women, at-the-market equity offering updates, and a commercial manufacturing and supply agreement for ORLYNVAH™ bilayer tablets. Other 8-K filings describe annual general meeting voting results and shareholder approvals or rejections of proposals related to authorized share capital, equity incentive plans and director authorities.
Filings also document Nasdaq listing compliance matters. In 2025, Iterum reported receiving Nasdaq notices regarding non-compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Listing Rule 5550(b)(2). These filings outline compliance periods, potential remedies and the possibility of appeals if delisting is proposed, while noting that the notices did not cause immediate delisting.
Through its periodic and current reports, Iterum describes non-GAAP financial measures, royalty-linked notes, license and milestone obligations, and the role of its commercialization partner EVERSANA in the U.S. launch of ORLYNVAH™. Proxy-related filings and meeting results provide insight into corporate governance and executive compensation decisions.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain key points from lengthy documents, including annual and quarterly reports and Form 4 insider transaction filings when available. Real-time updates from EDGAR ensure that users can monitor new Iterum Therapeutics filings as they are posted and quickly understand how they relate to the company’s anti-infective business and Nasdaq listing profile.
Iterum Therapeutics plc reports that its ordinary shares will be delisted from Nasdaq after the company withdrew its appeal of a prior Nasdaq delisting determination tied to failing the $1.00 minimum bid price requirement. Trading will be suspended at the opening of business on April 1, 2026, with a Form 25-NSE to remove the shares from listing.
The company has filed a Winding Up Petition in the Irish High Court and is in provisional liquidation. Given limited cash and the ongoing winding up process, Iterum does not expect to file its Form 10-K for the year ended December 31, 2025 or make future SEC filings.
Iterum Therapeutics plc has filed a petition in the Irish High Court to wind up the company, and provisional liquidators from Teneo Restructuring have been appointed pending a court hearing on April 13, 2026. If a winding up order is granted, this will lead to the company’s dissolution.
The petition triggers an event of default on Iterum’s royalty-linked subordinated notes, causing interest to step up to the prime rate plus three percent and allowing holders to sue for payment. Board authority has effectively passed to the provisional liquidators, the CEO and CFO have resigned, Nasdaq trading in the shares is expected to be suspended, and the company warns that shareholders may face a significant or complete loss of their investment.
Iterum Therapeutics plc has requested a hearing with a Nasdaq Hearings Panel after receiving a determination letter stating its shares are scheduled for delisting from The Nasdaq Capital Market for failing to meet the $1.00 minimum bid price requirement. The hearing request temporarily halts suspension and delisting while the process plays out, but the company warns there is no assurance of a favorable outcome or any extension.
The company also does not meet Nasdaq’s $35 million minimum market value of listed securities standard and related shareholders’ equity or net income requirements, and must show the Panel it can regain and sustain compliance by June 9, 2026. Iterum is evaluating corporate, strategic and financial alternatives, including potential asset sales, strategic transactions, or a wind-down. It cautions that, given its limited ability to raise capital, a bankruptcy, liquidation, dissolution or similar outcome is possible, in which shareholders are very unlikely to receive any meaningful return.
Iterum Therapeutics plc reports it has received a Nasdaq delisting determination after ongoing failure to meet the $1.00 minimum bid price requirement. Nasdaq plans to suspend trading of its ordinary shares from March 5, 2026 and subsequently file a Form 25-NSE to complete delisting.
The company also remains out of compliance with Nasdaq’s $35 million minimum market value of listed securities standard and related equity or net income requirements. Iterum is evaluating corporate, strategic and financial alternatives, including a potential wind-down or bankruptcy, where shareholders are described as very unlikely to receive any meaningful return.
Iterum Therapeutics plc reported that shareholders at an extraordinary general meeting did not approve four key proposals: an increase in authorized share capital, expanded director authority to issue securities, an opt-out from pre-emption rights, and a reverse share split consolidating 10–15 shares into one. Each proposal received more votes against than for. The company states that these results restrict its ability to raise additional capital and indicate that its operations, financial condition, and ability to continue as a going concern are likely to be materially and adversely affected. Iterum is evaluating options such as asset or technology sales, strategic transactions, or a wind-down, and notes that in a bankruptcy, liquidation, dissolution or similar outcome, shareholders would be very unlikely to receive any meaningful return.
Iterum Therapeutics plc has received a notice from Nasdaq that it no longer meets the Nasdaq Capital Market’s continued listing standards for market value and certain financial criteria. On December 11, 2025, Nasdaq stated that Iterum’s Market Value of Listed Securities had stayed below $35 million for 30 consecutive business days, violating Listing Rule 5550(b)(2), and that the company also fails the alternative shareholder equity and net income requirements.
Iterum has 180 calendar days, until June 9, 2026, to restore its market value to at least $35 million for a minimum of 10 consecutive business days or face potential delisting, with a right to appeal. The company also remains out of compliance with Nasdaq’s $1.00 minimum bid price rule after a prior August 25, 2025 notice and has until February 23, 2026 to achieve a closing bid of at least $1.00 for 10 consecutive business days, with a possible additional 180‑day period if it meets other listing standards. Iterum’s shares continue to trade on Nasdaq for now while it works to regain compliance.
Iterum Therapeutics plc (ITRM) reported an insider share purchase by a director. On 11/18/2025, the director bought 6,000 ordinary shares at a price of $0.3652 per share in an open-market transaction coded "P." Following this trade, the director beneficially owned 241,001 ordinary shares, held as a direct ownership position. No derivative securities transactions were reported in this filing.
Iterum Therapeutics (ITRM) filed its Q3 2025 report highlighting early commercialization and liquidity pressure. The company recorded its first product revenue of $390 thousand from ORLYNVAH™, launched in August 2025, while posting a net loss of $8.98 million for the quarter. Operating expenses rose with commercialization, including $6.49 million in selling, general and administrative costs and $1.26 million in R&D.
Cash and cash equivalents were $11.0 million as of September 30, 2025, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing. Net cash used in operating activities was $15.26 million for the nine months. The balance sheet shows a shareholders’ deficit of $7.38 million, a Pfizer promissory note of $21.22 million, and royalty-linked notes of $12.24 million long-term and $0.28 million current. ORLYNVAH™ revenue is modest at launch, reflecting early-stage uptake through EVERSANA’s commercialization platform.
Shares outstanding were 52,787,679 as of November 13, 2025. Results underscore commercialization progress but also the need for capital to support operations and market expansion.
Iterum Therapeutics plc filed a Form 8-K announcing it has furnished a press release with its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information is being furnished—not deemed “filed” under Section 18 of the Exchange Act—and will not be incorporated by reference into other SEC filings. The filing is administrative in nature and includes the Inline XBRL cover page as Exhibit 104.
Iterum Therapeutics plc filed a prospectus supplement to sell up to $20,000,000 of ordinary shares in an at-the-market program through H.C. Wainwright & Co., not to exceed 21,756,057 ordinary shares. Sales may be made on the Nasdaq Capital Market or by other permitted methods, with Wainwright acting as sales agent.
The program is limited to the company’s authorized but unissued share capacity. Based on 21,756,057 shares currently available for issuance and an assumed price of $0.7377, the company indicates it could sell up to approximately $16,049,443 under the agreement. Iterum will pay a 3.0% sales commission to Wainwright and would receive the net proceeds.
This supplement supersedes the prior ATM supplement, moving the remaining $4,775,345 capacity under that document into this one. Iterum reports aggregate gross proceeds of approximately $36.2 million previously raised under the sales agreement. Ordinary shares outstanding were 48,051,157 as of September 15, 2025. The shares trade on Nasdaq as “ITRM.”